| 7537 |
From BTK in-situ mutation (C481S, A428D, etc.) to in vivo screening: A comprehensive platform to address drug resistance in BTK-targeted therapy |
32 |
18 |
4/22/2026 9:00 |
| 7536 |
In vitro and in vivo screening platform for discovery of JAK2 inhibitors |
32 |
17 |
4/22/2026 9:00 |
| 2143 |
From local growth to distant metastasis: A versatile in vivo imaging platform for modeling cancer progression |
28 |
15 |
4/20/2026 9:00 |
| 5851 |
(Common-light-chain-antibody+nano-body) × multi-matrix-immunization platform facilitates the development of antitumor multispecific antibody drugs |
20 |
17 |
4/21/2026 2:00 |
| 741 |
Illuminate your targets: Endogenous HiBiT knock-in monoclones — inventory + rapid custom |
30 |
11 |
4/19/2026 2:00 |
| 2174 |
A comprehensive CRISPR/Cas9-based RAS knock-in cell line platform (50+ models) for assessing the efficacy of KRAS-targeted inhibitors in RAS-mutant malignancies. |
29 |
25 |
4/20/2026 9:00 |
| 7229 |
TM-PAP, everywhere you need it: Cross-species, multi-host panel for fast readouts |
18 |
21 |
4/22/2026 9:00 |
| 2759 |
An innovative AI-based platform for antibody stability improvement and affinity optimization |
3 | 23 |
4/20/2026 2:00 |
| 1650 |
MPSA-AB5000: A high-throughput cell-based membrane protein screening array for accurate early-stage off-target assessment to accelerate safer antibody therapeutic development |
11 |
9 |
4/20/2026 9:00 |
| 1806 |
WRN under the scalpel: Helicase-domain hotspot & splice-site knock-ins in HCT116 and RKO |
16 |
26 |
4/20/2026 9:00 |
| 7535 |
Over 800! Establishment of an ADC payload efficacy database across diverse tumor cell lines: Foundation for optimized in vitro ADC evaluation and drug development |
32 |
16 |
4/22/2026 9:00 |
